Diane-Laure Pagès
Co-founder & COO
at
Orakl Oncology
Diane-Laure Pagès, PhD, is the Co-founder & COO of Orakl Oncology, and she’s pushing science forward to improve patient lives. She started her journey in top French engineering and research institutions - École polytechnique, ENS, and later a PhD in biology at Gustave Roussy, Europe’s leading cancer center - where she published cutting-edge work in top-tier journals. Trained in both science and entrepreneurship, she built expertise at the crossroads of biology, data, and strategic project management.
She launched Orakl Oncology, a spin-off of Gustave Roussy, in 2023 with Fanny Jaulin, PhD (CEO) and Gustave Ronteix, PhD (CTO) which raised €15m+. Orakl’s mission is to disrupt oncology drug development with a first-in-class, AI-native predictive platform. By integrating patient-derived biology, advanced AI, and real-world clinical data, Orakl uncovers novel drug targets, predicts patient responses, and accelerates the journey from discovery to clinical success. They are unlocking a new era where life-saving therapies reach patients faster, safer, and with radically higher precision. Orakl is on a mission to revolutionize oncology drug development and make cancer a manageable chronic disease.